|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C18orf8 |
Gene summary for C18ORF8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C18orf8 | Gene ID | 29919 |
| Gene name | regulator of MON1-CCZ1 | |
| Gene Alias | C18orf8 | |
| Cytomap | 18q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006914 | UniProtAcc | A0A087WZD4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29919 | C18orf8 | P1T-E | Human | Esophagus | ESCC | 1.35e-06 | 3.97e-01 | 0.0875 |
| 29919 | C18orf8 | P2T-E | Human | Esophagus | ESCC | 3.56e-17 | 2.62e-01 | 0.1177 |
| 29919 | C18orf8 | P4T-E | Human | Esophagus | ESCC | 4.66e-21 | 3.49e-01 | 0.1323 |
| 29919 | C18orf8 | P5T-E | Human | Esophagus | ESCC | 1.68e-13 | 2.50e-01 | 0.1327 |
| 29919 | C18orf8 | P8T-E | Human | Esophagus | ESCC | 1.13e-14 | 2.39e-01 | 0.0889 |
| 29919 | C18orf8 | P9T-E | Human | Esophagus | ESCC | 1.21e-12 | 3.91e-01 | 0.1131 |
| 29919 | C18orf8 | P10T-E | Human | Esophagus | ESCC | 4.65e-14 | 1.60e-01 | 0.116 |
| 29919 | C18orf8 | P11T-E | Human | Esophagus | ESCC | 4.46e-09 | 2.42e-01 | 0.1426 |
| 29919 | C18orf8 | P12T-E | Human | Esophagus | ESCC | 8.83e-14 | 3.26e-01 | 0.1122 |
| 29919 | C18orf8 | P15T-E | Human | Esophagus | ESCC | 3.79e-20 | 3.19e-01 | 0.1149 |
| 29919 | C18orf8 | P16T-E | Human | Esophagus | ESCC | 1.01e-09 | 1.28e-01 | 0.1153 |
| 29919 | C18orf8 | P17T-E | Human | Esophagus | ESCC | 3.27e-03 | 2.33e-01 | 0.1278 |
| 29919 | C18orf8 | P20T-E | Human | Esophagus | ESCC | 1.86e-12 | 3.24e-01 | 0.1124 |
| 29919 | C18orf8 | P21T-E | Human | Esophagus | ESCC | 1.75e-26 | 4.99e-01 | 0.1617 |
| 29919 | C18orf8 | P22T-E | Human | Esophagus | ESCC | 5.81e-17 | 2.98e-01 | 0.1236 |
| 29919 | C18orf8 | P23T-E | Human | Esophagus | ESCC | 4.06e-26 | 5.59e-01 | 0.108 |
| 29919 | C18orf8 | P24T-E | Human | Esophagus | ESCC | 2.19e-16 | 2.89e-01 | 0.1287 |
| 29919 | C18orf8 | P26T-E | Human | Esophagus | ESCC | 8.71e-14 | 3.16e-01 | 0.1276 |
| 29919 | C18orf8 | P27T-E | Human | Esophagus | ESCC | 7.74e-18 | 3.10e-01 | 0.1055 |
| 29919 | C18orf8 | P28T-E | Human | Esophagus | ESCC | 2.06e-22 | 3.44e-01 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C18orf8 | SNV | Missense_Mutation | rs764730840 | c.808N>A | p.Val270Met | p.V270M | Q96DM3 | protein_coding | deleterious(0) | possibly_damaging(0.849) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
| C18orf8 | SNV | Missense_Mutation | novel | c.1405N>A | p.Val469Met | p.V469M | Q96DM3 | protein_coding | tolerated(0.07) | benign(0.204) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C18orf8 | SNV | Missense_Mutation | novel | c.1148G>T | p.Arg383Ile | p.R383I | Q96DM3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-VS-AA62-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| C18orf8 | SNV | Missense_Mutation | c.199N>A | p.Val67Met | p.V67M | Q96DM3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C18orf8 | SNV | Missense_Mutation | c.226N>T | p.Asn76Tyr | p.N76Y | Q96DM3 | protein_coding | tolerated(0.16) | benign(0.289) | TCGA-AA-3955-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | capecitabine | CR | |
| C18orf8 | SNV | Missense_Mutation | novel | c.1670N>A | p.Arg557Gln | p.R557Q | Q96DM3 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| C18orf8 | SNV | Missense_Mutation | novel | c.1196N>T | p.Ser399Ile | p.S399I | Q96DM3 | protein_coding | tolerated(0.27) | benign(0) | TCGA-AA-A02W-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| C18orf8 | SNV | Missense_Mutation | c.490N>A | p.Ala164Thr | p.A164T | Q96DM3 | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| C18orf8 | SNV | Missense_Mutation | c.136N>A | p.Val46Met | p.V46M | Q96DM3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C18orf8 | SNV | Missense_Mutation | rs753034758 | c.397N>A | p.Glu133Lys | p.E133K | Q96DM3 | protein_coding | deleterious(0) | benign(0.027) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |